18.76
前日終値:
$19.07
開ける:
$19.23
24時間の取引高:
29,638
Relative Volume:
0.75
時価総額:
$64.47M
収益:
-
当期純損益:
$-17.92M
株価収益率:
-2.6793
EPS:
-7.0019
ネットキャッシュフロー:
$-17.78M
1週間 パフォーマンス:
+6.77%
1か月 パフォーマンス:
+66.61%
6か月 パフォーマンス:
-75.18%
1年 パフォーマンス:
-68.68%
Eloxx Pharmaceuticals Inc Stock (ELOX) Company Profile
Compare ELOX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ELOX
Eloxx Pharmaceuticals Inc
|
18.76 | 62.76M | 0 | -17.92M | -17.78M | -7.0019 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eloxx Pharmaceuticals Inc Stock (ELOX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-17 | 開始されました | Oppenheimer | Outperform |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | 開始されました | B. Riley Securities | Buy |
| 2020-06-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-06 | 開始されました | Janney | Buy |
| 2018-12-24 | 開始されました | H.C. Wainwright | Neutral |
| 2018-07-03 | 開始されました | Citigroup | Buy |
すべてを表示
Eloxx Pharmaceuticals Inc (ELOX) 最新ニュース
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Eloxx Pharmaceuticals Q2 net loss widens on higher expenses - TradingView
Eloxx Plans Phase 2b Alport Trial in Q3 After ~$66M Offering - Stock Titan
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering - TradingView
Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary - TradingView
ELOX: Raised $58.3M in public offering, advancing exaluren trials amid rising operating losses - TradingView
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
Eloxx Pharmaceuticals (ELOXD) Financials 2026Income Statement and Balance Sheet - MarketBeat
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:11.940|Chg%:-0.060 - TradingKey
Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX - TradingView
Enterprise value to EBIT forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Price to earnings forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
Eloxx Pharmaceuticals (ELOX) Registration filing Summary - Quartr
Eloxx Pharmaceuticals (ELOX) Q1 2026 earnings summary - Quartr
LifeSci Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $40 - Moomoo
Guggenheim Initiates Eloxx Pharmaceuticals at Buy With $43 Price Target - marketscreener.com
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim - TipRanks
Guggenheim initiates Eloxx Pharma stock with buy on kidney data By Investing.com - Investing.com Canada
Guggenheim Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $43 - Moomoo
ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart - mexc.co
Eloxx Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Price to book forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock trades on Nasdaq as small-cap biotech focuses on cystic fibrosis therapy - Ad-hoc-news.de
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:12.270|Chg%:+1.320 - TradingKey
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - AOL.com
Price to sales forward of Eloxx Pharmaceuticals, Inc. – BOATS:ELOX - TradingView
Enterprise value to EBITDA forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Eloxx Pharma (ELOX) Stock Analysis Report | Financials & Insights - Benzinga España
Eloxx’s EXACT Study Puts Exaluren in Focus for Rare Kidney Disease Investors - TipRanks
ELOXEloxx Pharmaceuticals Inc Latest SEC Filings - Finviz
Enterprise value to revenue forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX SEC FilingsEloxx Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Eloxx Pharmaceuticals StockSaturday view on pipeline and business model - AD HOC NEWS
Coastlands (NASDAQ: ELOX) discloses 410,530 shares, 9.99% stake - Stock Titan
Domicilium group discloses 19.99% stake in Eloxx (NASDAQ: ELOX) - Stock Titan
Eloxx (ELOX) 10% holder swaps Pre-Funded Warrants into common stock - Stock Titan
Domicilium Real Estate Fund III (ELOX) details Eloxx stock and warrant stakes - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
EcoR1, affiliates report ~9.9% holdings in Eloxx (NASDAQ: ELOX) - Stock Titan
Stonepine-affiliated holders report 403,228 shares in Eloxx (ELOX) — 9.9% stake - Stock Titan
Invus-led group holds 9.99% of Eloxx (ELOX) via shares and warrants - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Eloxx Pharmaceuticals: Shares Expected to Start Trading on Nasdaq Capital Market on June 9 >ELOX - Moomoo
ELOX Technical Analysis & ETF Price Forecast - Intellectia AI
Eloxx Pharmaceuticals Inc (ELOX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):